CPT® Code 90386

1. Indications

The Rho(D) immune globulin (RhIgIV) is indicated for use in specific clinical scenarios where passive immunity is required to prevent Rh incompatibility reactions. The following conditions warrant the administration of this immunizing agent:

• Pregnancy with Rh Incompatibility - Administered to Rh-negative mothers who are carrying an Rh-positive fetus to prevent hemolytic disease of the newborn.
• Blood Transfusions - Used in cases where Rh-negative individuals receive Rh-positive blood to prevent potential immune reactions.

2. Procedure

The administration of Rho(D) immune globulin (RhIgIV) involves several critical procedural steps to ensure safety and efficacy. The following outlines the detailed steps involved in the procedure:

• Step 1: Patient Assessment - Prior to administration, a thorough assessment of the patient’s medical history and current health status is conducted. This includes confirming the Rh status of the patient and determining the necessity for RhIgIV based on clinical indications.
• Step 2: Preparation of the Product - The Rho(D) immune globulin is prepared according to the manufacturer's guidelines. This includes checking the product for integrity, expiration date, and ensuring it is at the appropriate temperature for administration.
• Step 3: Administration - The immune globulin is administered intravenously, typically through a slow infusion to monitor for any adverse reactions. The healthcare provider must ensure that the infusion is performed in a controlled environment where the patient can be observed for any immediate side effects.
• Step 4: Monitoring - After administration, the patient is monitored for any signs of allergic reactions or other adverse effects. Vital signs are checked regularly, and the patient is observed for a specified period to ensure their safety.

3. Post-Procedure

Following the administration of Rho(D) immune globulin (RhIgIV), patients are typically advised to remain under observation for a designated period to monitor for any potential adverse reactions. It is essential to provide the patient with information regarding possible side effects, which may include mild fever, rash, or allergic reactions. Patients should also be instructed to report any unusual symptoms or reactions that may occur after leaving the healthcare facility. Documentation of the administration, including the lot number of the immune globulin and the patient's response, is crucial for compliance and future reference. Additionally, follow-up appointments may be scheduled to assess the effectiveness of the treatment and to monitor the patient's Rh status in subsequent pregnancies or transfusions.